Can a bone drug stop smoldering myeloma from becoming active cancer?
NCT ID NCT03839459
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 36 times
Summary
This study tested the safety of denosumab, a drug usually used for bone health, in 20 people with smoldering multiple myeloma (a pre-cancer condition). The goal was to see if denosumab could lower their risk of developing active multiple myeloma. Researchers tracked changes in risk categories and whether the disease progressed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.